Carlton is the Fractional Chief Medical Officer at Xilis. He has over 25 years of experience in clinical cancer care operating upon and treating patients with pancreatic cancer, liver metastases, melanoma, and soft tissue malignancies. His research addresses immune-mediated tumor progression and metastases specifically targeting novel mechanisms to mitigate tumor growth in cancers that have traditionally not responded to standard chemotherapies. He brings a wealth of clinical experience and translational science to the diagnostic space. He received his MD from the University of Colorado and Fellowship training at the University of Texas MD Anderson Cancer Center.
Carlton is the Fractional Chief Medical Officer at Xilis. He has over 25 years of experience in clinical cancer care operating upon and treating patients with pancreatic cancer, liver metastases, melanoma, and soft tissue malignancies. His research addresses immune-mediated tumor progression and metastases specifically targeting novel mechanisms to mitigate tumor growth in cancers that have traditionally not responded to standard chemotherapies. He brings a wealth of clinical experience and translational science to the diagnostic space. He received his MD from the University of Colorado and Fellowship training at the University of Texas MD Anderson Cancer Center.
Kendra is Vice President of Assay Development at Xilis. She has over 20 years of pharmaceutical industry experience that spans research and development to manufacturing and small biotech to large pharma companies. Her broad foundation in the biological and chemical sciences, capabilities as a scientific and business leader, and enthusiasm for drug discovery have enabled her to make significant contributions to a wide range of assets, technologies, targets, modalities, and therapeutic areas. Kendra was previously Vice President of Lead Discovery at Ribometrix and Vice President of Lead Generation at Enveda Biosciences. She received her PhD in biology from Johns Hopkins University.
Kendra is Vice President of Assay Development at Xilis. She has over 20 years of pharmaceutical industry experience that spans research and development to manufacturing and small biotech to large pharma companies. Her broad foundation in the biological and chemical sciences, capabilities as a scientific and business leader, and enthusiasm for drug discovery have enabled her to make significant contributions to a wide range of assets, technologies, targets, modalities, and therapeutic areas. Kendra was previously Vice President of Lead Discovery at Ribometrix and Vice President of Lead Generation at Enveda Biosciences. She received her PhD in biology from Johns Hopkins University.
Hans is General Counsel at Xilis. As a registered patent attorney, he has developed intellectual-property portfolios and counseled research institutions and companies on legal strategy across the medical-device and pharmaceutical industries. Hans received his B.S. in Engineering & Applied Science from the California Institute of Technology, his Master of Business & Science (MBS) from the Keck Graduate Institute Henry E. Riggs School of Applied Life Sciences, his J.D. from the Drexel University Thomas R. Kline School of Law, and a Certified Information Privacy Professional/United States (CIPP/US) certification from the International Association of Privacy Professionals.
Hans is General Counsel at Xilis. As a registered patent attorney, he has developed intellectual-property portfolios and counseled research institutions and companies on legal strategy across the medical-device and pharmaceutical industries. Hans received his B.S. in Engineering & Applied Science from the California Institute of Technology, his Master of Business & Science (MBS) from the Keck Graduate Institute Henry E. Riggs School of Applied Life Sciences, his J.D. from the Drexel University Thomas R. Kline School of Law, and a Certified Information Privacy Professional/United States (CIPP/US) certification from the International Association of Privacy Professionals.